Programmatic screening for latent tuberculosis in migrants
- PMID: 35338848
- DOI: 10.1016/S2468-2667(22)00064-0
Programmatic screening for latent tuberculosis in migrants
Conflict of interest statement
MP reports grants from Sanofi; grants and personal fees from Gilead Sciences; and personal fees from QIAGEN, outside the submitted work. CG reports an investigator-initiated grant from Gilead Sciences and consultant fees from Abbvie, outside the submitted work. The views expressed in the publication are those of the authors and not necessarily those of the National Health Service, the NIHR, or the Department of Health and Social Care.
Comment on
-
Effectiveness of nationwide programmatic testing and treatment for latent tuberculosis infection in migrants in England: a retrospective, population-based cohort study.Lancet Public Health. 2022 Apr;7(4):e305-e315. doi: 10.1016/S2468-2667(22)00031-7. Epub 2022 Mar 23. Lancet Public Health. 2022. PMID: 35338849 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
